14本のエピソード

A podcast about the life sciences and science policy produced by EMBO.

The EMBO podcast EMBO

    • 科学

A podcast about the life sciences and science policy produced by EMBO.

    Proteomics and personalised medicine

    Proteomics and personalised medicine

    6 May 2022 - The amazing advances in gene sequencing technology over the last two decades have not yet sparked the revolution in personalized cancer treatment that many had hoped for. Although there have been significant advances,  actionable mutations, those that can be targeted to improve patient survival or quality of life, remain rare. But there is also the option to leapfrog genomics entirely, or to complement it, by using proteomic approaches. You may be surprised to learn that, as the guests on this episode of our podcast, Ursula Klingmüller and Matthias Mann told us, clinical proteomics is already being explored to design personalized cancer treatment strategies. Klingmüller and Mann discussed the technological (read the Mann lab’s recent Molecular Systems Biology paper on single cell proteomics here), scientific, and clinical challenges of the field with Molecular Systems Biology Senior Scientific Editor Maria Polychronidou.

    • 43分
    “I learned early on that you can do a lot with a small amount of money”

    “I learned early on that you can do a lot with a small amount of money”

    21 March 2022 - Fiona Watt has been recently appointed EMBO Director, taking over from Maria Leptin, who was inaugurated as the new president of the European Research Council in the fall of 2021. Fiona and Maria sat down to discuss science funding, what scientists get wrong about interacting with policymakers, the importance of failure, and much more. The conversation took place in Heidelberg, not long after the start of the war in Ukraine, and we also talked about EMBO’s Solidarity List for displaced researchers.

    • 46分
    From cell death to cancer immunotherapy

    From cell death to cancer immunotherapy

    3 March 2022 - In the November 1992 issue of The EMBO Journal, Tasuku Honjo and colleagues reported the discovery of a new gene, which they named programmed death 1 (PD-1). Thirty years later, monoclonal antibodies against PD-1 were being used in the clinic to treat cancer patients, and in 2018 Tasuku Honjo shared the Nobel Prize for Physiology or Medicine with James Allison. “The paper has been transformational. I don’t think that they would ever have predicted that looking into genes that were differentially expressed that they would get such an important molecule that would be transformative for cancer immunotherapy,” said EMBO Journal Chief Editor Facundo Batista. In this episode of the EMBO podcast, Tasuku Honjo spoke about his journey from medical school to basic research, the importance of academic journals, and the many surprising turns in the PD-1 story. We also talked to Pierre Golstein, whose group cloned CTLA-4.

    • 31分
    EMBO Young Investigators past and present

    EMBO Young Investigators past and present

    16 February 2022 - The EMBO Young Investigator Programme (YIP) was created in 2002 to support researchers starting their first lab (to be eligible, “applicants must have been an independent group leader for at least one year and for less than four years”). The programme provides mentorship, training, and networking opportunities for both the PIs and their lab members. Applications for the YIP programme are currently open. The EMBO podcast spoke with a YIP alumnus, immunologist Matteo Iannacone, and a recently selected member of the programme, neuroscientist Katrin Franke.

    • 44分
    “These papers are the best papers that we’ve ever produced”

    “These papers are the best papers that we’ve ever produced”

    2 February 2022 - Cell biologist Prachee Avasthi has a longstanding interest in cilia, which she began studying in mammalian photoreceptor cells as a graduate student, before adopting the single-cell green alga Chlamydomonas reinhardtii as her model organism. Prachee was recently appointed Chief Scientific Officer of the newly created Arcadia Science, and she also serves as president of the non-profit science organization ASAPbio. ASAPbio is EMBO’s partner in the peer-reviewed preprint platform, Review Commons. Prachee and Review Commons project leader Thomas Lemberger joined the EMBO podcast for a discussion on open science, preprints, peer review, and the importance of community.

    • 44分
    The right place at the right time

    The right place at the right time

    3 January 2021 - “Mucosal immunity is likely the best strategy to go forward fighting this pandemic. It’s like placing the guard outside the door instead of inside the door,” immunologist Akiko Iwasaki told the EMBO podcast. Iwasaki has been studying how the immune system fights infections at the interfaces between the host and the environment ever since graduate school when she challenged the prevailing dogma about how DNA vaccines work. Her lab has made fundamental contributions to our understanding of the pathophysiology of COVID-19, using patient samples and data, as well as developing new model systems. We discussed her research, some of the challenges of science communication during the pandemic, and her approach to teaching.



    Akiko Iwasaki was elected an EMBO Associate Member in 2021.

    • 37分

科学のトップPodcast

NewsPicks
研究者レン & OLエマ
ニッポン放送
そんないプロジェクト
ゆる数学ラジオ
いんよう!

その他のおすすめ

BBC World Service
Science Magazine
Vincent Racaniello
Andreessen Horowitz